Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a report issued on Wednesday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Trading Down 5.5 %

Shares of NASDAQ CHEK opened at $0.61 on Wednesday. The stock has a market cap of $3.59 million, a P/E ratio of -0.20 and a beta of 0.25. Check-Cap has a twelve month low of $0.61 and a twelve month high of $3.45. The stock has a 50 day moving average of $1.06 and a two-hundred day moving average of $1.63.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.